knowledge -WSS

knowledge

author：hotspot 2025-09-30 01:01:12 - browse：4

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： NIH documents show early flaws of $1.6 billion long Covid program

Wikipedia

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Woman returns to dialysis after doctors remove transplanted pig kidney

Will the market for weight loss drugs really reach $100 billion?

Mayo Clinic plans $5B tech

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Letters to First Opinion on caregivers, digital health, and more

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

ReNAgade cuts staff seven months after raising $300 million

Moonlake's readout produced a cash windfall. Risks remain

Organ aging and disease risk measured by new blood test

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cigna, Humana reportedly in talks to merge

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

At least 13 dead in Texas as scorching temps continue

ASCO: Palliative care found as helpful given virtually as in person

leisure time

The Pandemic Treaty must support building strong health systems

FDA investigates CAR

ASCO: Palliative care found as helpful given virtually as in person

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

J&J to emphasize cancer drugs, stop much of its vaccine research

entertainment

hotspot

Wikipedia

focus